NCT04583228
Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects
Phase: Phase 1
Role: Lead Sponsor
Start: Apr 8, 2021
Completion: Jul 20, 2021